Skip to main content
OpenTrials
Completed

NCT Number: NCT03419364

Study of Nicotinamide in Early Onset Preeclampsia

Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

UNC at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

About this study

See brief summary above

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Diagnosis and Inclusion Criteria

  • Maternal age 18-55 years
  • Singleton pregnancy with no known fetal anomalies
  • Early-onset preeclampsia OR early-onset severe gestational hypertension defined as:
  • Early-onset: between 24 weeks 0 days and -33 weeks 3 days, based on menstrual dating confirmed by first or second trimester ultrasound OR second trimester ultrasound if menstrual dating unavailable;
  • Preeclampsia:
  • New onset hypertension and proteinuria, with systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart and > 300 mg proteinuria on 24 hour urine collection OR urine P/C ratio >0.3;
  • New onset hypertension and NO proteinuria, with systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg on two occasions 6 hours apart and one or more of the following: serum creatinine >1.1 mg/dL or doubling from baseline ,or central nervous system symptoms or visual changes
  • Severe preeclampsia defined as new onset systolic BP > 160 mm Hg and/or diastolic BP > 105 with proteinuria as above or or without proteinuria and one or more of the following criteria listed above
  • Candidate for expectant management for at least 48 hours
  • Deemed clinically stable by primary clinician and candidate for expectant management (delayed delivery) for at least 48 hours;
  • Maternal liver function tests < 2x ULN
  • Maternal platelet count > 100,000 mm³
  • Planned expectant management
  • Pre-existing medical diseases such as hypertension, diabetes, endocrine disorders, gastrointestinal diseases, are well controlled
  • Fetal well-being established by estimated fetal weight > 5th %tile; normal amniotic fluid volume (MVP > 2 cm); normal Umbilical Artery (UA) Dopplers; or reactive Non Stress Test (NST) or Biophysical Profile (BPP) > 6
  • Delivery not anticipated within 48 hours of enrollment

Exclusion criteria

  • Pre-existing renal disease (creatinine > 1.5 mg/dL)
  • Any pre-existing medical condition that would increase risk for liver toxicity (e.g. hepatitis B or C; HIV; Isoniazid (INH) use)
  • Eclampsia; cerebral edema on CT/MRI; headache unrelieved by analgesics
  • Evidence of liver dysfunction (LFTs > 2x ULN)
  • Thrombocytopenia (platelets < 100,000 mm³)
  • Pulmonary edema
  • HELLP syndrome
  • Evidence of fetal compromise: Estimated Fetal Weight (EFW) < 5th percentile; or BPP < 6; or absent or reverse diastolic UA blood flow; or oligohydramnios (MVP < 2 cm)
  • Placental abruption defined as unexplained vaginal bleeding
  • Preterm labor defined as regular contractions and cervical change
  • Any condition deemed by the investigator to be a risk to mother or fetus in completion of the study
  • Any condition deemed by the investigator to require delivery within 48 hours

Treatment and study plan

Nicotinamide

Drug

2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday

Other names: niacinamide

Primary outcomes

  1. Change in Mean Arterial Blood Pressure (MAP)

    Time frame: Baseline, 48 hours

    Blood pressure (mmHg) will be used to observe the effect of nicotinamide. The highest MAP (defined as the highest MAP within the 24 hour period prior to the administration of study agent) and the highest MAP through 24 hours after study drug administration.

Secondary outcomes

  1. Number of Participants With Alanine Aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)

    Time frame: Within 24 hours of any dose, up to a maximum 4 weeks

  2. Number of Participants With Aspartate Aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)

    Time frame: Within 24 hours of any dose, up to a maximum 4 weeks

  3. Number of Participants With Maternal Side Effects

    Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

    Maternal side effects are defined as: facial erythema, hives, sore mouth, dry hair, fatigue, flushing, headache, nausea, and heart burn.

  4. Percentage of Women Maternal Abdominal Tenderness

    Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

  5. Percentage of Women With Headache Unrelieved by Oral Analgesics

    Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

  6. Percentage of Women With Hematocrit Decrease of More Than 3%

    Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

  7. Percentage of Women With Less Than 500 cc Urine Output in 24 Hours

    Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

  8. Percentage of Fetuses With Category III Non Stress Test Results

    Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

    A Non Stress Test is a determination of the current well-being of the fetus, as measured by the fetal heart rate. Category I indicates that the fetus is in a state of well-being and is tolerating the intrauterine environment. Category II indicates a fetal heart rate that is showing some signs of distress. In this instance, obstetric providers will try to improve the intrauterine environment to allow the pregnancy to continue. Category III relates to a fetus whose well-being is compromised - usually requiring rapid intervention, ie expedient delivery.

  9. Percentage of Fetuses With Biophysical Profile < 6

    Time frame: From initial administration of study agent until 24 hours post last dose

  10. Mean Peak Nicotinamide Level

    Time frame: at 1 hour post 1000 mg nicotinamide administration on Day 1

    The mean was calculated for each group using blood samples drawn on Day 1 at 1 hour post 1000 mg nicotinamide administration routinely given at 8 a.m. Peak nicotinamide level expected at 1 hour post dose.

  11. Mean Trough Concentration Nicotinamide Administration

    Time frame: 8 hours after the 8 a.m. 1000 mg nicotimamide administration on Day 1

    The mean was calculated for each group for blood samples drawn on Day 1 8 hours post 1000 mg nicotinamide administration routinely given at 8 a.m. Trough nicotinamide level is measured immediately prior to the next dose.

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Official study title

Phase II Study of Nicotinamide in Early Onset Preeclampsia

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Feb 1, 2018
Registry last updated
Sep 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.